Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC

This study tests a two-step treatment approach for advanced triple-negative breast cancer (a subtype that is harder to treat) that has a specific marker called PD-L1. Patients first receive a combination of chemotherapy drugs, then switch to an immunotherapy-based regimen. **You may be eligible if...** - You are 18 or older with metastatic or unresectable triple-negative breast cancer - Your tumor tests positive for PD-L1 (a marker that helps predict response to immunotherapy) - You have not received prior treatment for advanced disease (or relapsed at least 6 months after completing earlier treatment) - Your overall health status is adequate (ECOG 0–1) **You may NOT be eligible if...** - Your tumor is PD-L1 negative - You have already received immunotherapy for advanced disease - You have active brain metastases - You have significant heart or organ problems Talk to your doctor to see if this trial is right for you.